Company intelligence / Profile preview

BluAct Technologies

Zurich, Zurich, Switzerlandbluact.com ↗

Ownership: Private
Development stage: Commercial

Overview

BluAct Technologies has developed and commercialized proprietary water purification solutions based on amyloid fibril-carbon hybrids. Their products demonstrate >99% efficiency in removing heavy metals and organic contaminants from drinking and industrial waters. The technology is certified to NSF 53 standards for heavy metal removal and is used globally in regions with severe groundwater contamination.

Modalities: DeviceNanomaterial-based filtration media (Amyloid fibril-carbon hybrid)
Industry: Non-Drug Biotech

Partnerships

Complies with international standards/certifications such as NSF53; no major pharma or biotech partnerships reported.

Beyond the preview

Go deeper on BluAct Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BluAct Technologies.

Explore the full profile